Results 111 to 120 of about 2,125 (132)

Omega-3 Fatty Acids for the Treatment of Bipolar Disorder Symptoms: A Narrative Review of the Current Clinical Evidence. [PDF]

Mar Drugs
Psara E, Papadopoulou SK, Mentzelou M, Voulgaridou G, Vorvolakos T, Apostolou T, Giaginis C.   +6 more
europepmc   +1 more source

The risk of bone fractures in dementia patients receiving acetylcholinesterase inhibitors: a meta-analysis. [PDF]

Ann Med Surg (Lond)
Elhalag RH, Chèbl P, Bayoumy NM, Hassan NAIF, Hagar H, Abowafia M, Gaber H, Belal MM, Shah J, Motawea KR.   +9 more
europepmc   +1 more source

Designing and characterizing first Iranian study evaluating serum levels of lithium in patients for population pharmacokinetics (FIRELOLIPOP): baseline and first report. [PDF]

Sci Rep
Khakshoor MM, Pariz N, Askari VR, Fayyazi Bordbar MR, Honari S, Shirazinia M, Baradaran Rahimi V, Naghibi Sistani MB.   +7 more
europepmc   +1 more source

Predicting maintenance lithium response for bipolar disorder from electronic health records-a retrospective study. [PDF]

PeerJ
Hayes JF, Ben Abdesslem F, Eloranta S, Osborn DPJ, Boman M.   +4 more
europepmc   +1 more source

Impact of mood stabilizers on creativity. [PDF]

Australas Psychiatry
Parker G.
europepmc   +1 more source

Alternations of Plasma Fatty Acids in Patients With Bipolar Depression Under Acute Treatment of rTMS Combined With Quetiapine and Mood Stabilizer. [PDF]

Brain Behav
Yu H, Liang XJ, Qiao YT, Guo L, Li ZY, Zhou CH, Wu WJ, Li R, Peng ZW.   +8 more
europepmc   +1 more source

Depressive mania associated with nonresponse to antimanic agents [PDF]

American Journal of Psychiatry, 1993
Of 39 patients consecutively admitted for the treatment of primary mania, 21 (53.8%) simultaneously met the Research Diagnostic Criteria for major depressive disorder ("mixed" or "depressive" mania). Only nine (42.9%) of the 21 patients with depressive mania responded to antimanic agents.
Dilsaver Sc, Halle Mt, Bowers Tc, Alan C. Swann, Arif M. Shoaib   +4 more
  +6 more sources

The Ascendancy of Second-Generation Antipsychotics as Frontline Antimanic Agents

Journal of Clinical Psychopharmacology, 2015
Knowledge of the factors affecting the adoption of new medications can enhance mental health care and guide quality improvement and policy development. Food and Drug Administration indications for treating bipolar disorder with several second-generation antipsychotics (SGAs) in the 2000s represent an opportunity to identify factors that impact the ...
Mingfei Li, Laura Bajor, Samuel S. Nordberg, Fang Zhang, Robert B. Penfold, Christopher J. Miller, Austin F. Lee, David N. Osser, Mark S. Bauer, Eric G. Smith   +9 more
openaire   +4 more sources

Antimanic and mood‐stabilizing effect of memantine as an augmenting agent in treatment‐resistant bipolar disorder

Bipolar Disorders, 2010
Memantine is a selective, uncompetitive N-methyl- D-aspartate (NMDA) receptor antagonist, currently used in the treatment of Alzheimers disease. Many clinical trials have demonstrated its tolerability and safety. We have suggested that antidepressants induce mania and rapid cycling by sensitizing dopamine D2 receptors and demonstrated that the ...
Athanasios Koukopoulos, Daniela Reginaldi, SERRA, GIULIA, KOUKOPOULOS, ALEXIA, SANI, Gabriele, Gino Serra   +5 more
openaire   +5 more sources

A population‐based study of the comparative effectiveness of second‐generation antipsychotics vs older antimanic agents in bipolar disorder

Bipolar Disorders, 2016
ObjectivesNumerous antimanic treatments have been introduced over the past two decades, particularly second‐generation antipsychotics (SGAs). However, it is not clear whether such newer agents provide any advantage over older treatments.MethodsA historical cohort design investigated the nationwide population of outpatients with bipolar disorder treated
Mingfei Li, Mark S. Bauer, Austin Lee, Austin Lee, Christopher J. Miller, Christopher J. Miller, Laura Bajor   +6 more
openaire   +3 more sources